Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2) (MESAMI2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02462330 |
|
Recruitment Status :
Recruiting
First Posted : June 4, 2015
Last Update Posted : July 30, 2020
|
Sponsor:
University Hospital, Toulouse
Information provided by (Responsible Party):
University Hospital, Toulouse
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Stem cell therapy is an emerging treatment for cardiovascular disease but the best cell type and delivery method remain to be determined. Pre-clinical studies demonstrated improvement of cardiac function by Mesenchymal stem cells (MSC) therapy in particular by their paracrine and immunosuppressive properties. Investigators initiated the MESAMI program by the bicentric pilot phase and highlighted the safety and feasibility of intramyocardial injections of MSCs from bone marrow in patients with chronic ischemic cardiomyopathy and left ventricular dysfunction, guide by the NOGA-XP system. The MESAMI program continues with the phase 2, multicenter, double-blind, randomized, placebo-controlled trial.The aim of this phase 2 study is to demonstrate a functional improvement, measuring peak VO2, at 3 months between the cell therapy group and the placebo group.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Myocardial Ischemia | Drug: Autologous MSC from bone marrow Drug: Placebo comparator | Phase 2 |
Ischemic cardiomyopathies are a leading cause of death in both men and women. During the last decade, treatments for heart failure have evolved, but their purpose is to improve symptoms and prevent aggravation of the disease. Current research is focusing on the development of cell-based therapies using different sources of stem cells which can provide trophic and paracrine support or even replace dying cells with new ones. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. These cells are known for their ability to secrete paracrine factors and their immunosuppressive properties. The MESAMI 2 study will evaluate the efficacy of MSCs injection directly into the heart to repair and restore heart function in people with chronic ischemic heart failure using NOGA-XP system.
This phase 2 study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial. A total of 90 patients will be randomized in 2 arms to receive intramyocardial injection of MSCs or placebo. Patients will be followed up for 13 months. Bone marrow will be collected and immediately transported to the French Blood Establishment for MSC isolation and expansion. Patients will receive intramyocardial injection of MSCs or placebo during a left heart catheterization.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter. |
| Actual Study Start Date : | February 19, 2016 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Cardiomyopathy
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo comparator
injection of human albumin 4%
|
Drug: Placebo comparator
injections of human albumin
Other Name: Human Albumin |
|
Experimental: Autologous MSC from bone marrow
intramyocardial injection of 6.10e7 stem cells
|
Drug: Autologous MSC from bone marrow
After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
Other Name: mesenchymal stem cells |
Primary Outcome Measures :
- Change in VO2max [ Time Frame: 3 months ]Change in VO2max (or peak VO2) before injection and at 3 months post injection.
Secondary Outcome Measures :
- Left ventricular viability [ Time Frame: Before injection and at 3, 6 and 12 months ]MRI
- NYHA/CCS class [ Time Frame: Before injection and at 3, 6 and 12 months ]Change on class
- Quality of life (Minnesota questionnaire) [ Time Frame: Before injection and at 3, 6 and 12 months ]Change on quality of life test score
- VO2 max [ Time Frame: At 6 and 12 months ]Change in VO2max (or peak VO2) at 6 and 12 months post injection.
- 6'walking-test [ Time Frame: Between 3 and 12 months ]Distance to walk test
- Echocardiography [ Time Frame: Before injection and at 3, 6 and 12 months ]Volume of myocardium and measurement of ejection fraction
- Myocardial perfusion imaging [ Time Frame: Before injection and at 3, 6 and 12 months ]Efficacy of the cell therapy on LVEF
- BNP blood test [ Time Frame: Before injection and at 3, 6 and 12 months ]Change of the BNP blood test at 3, 6 and 12 months
Other Outcome Measures:
- Adverse event related to cell administration [ Time Frame: 12 months ]
- Complication related to cell administration [ Time Frame: 12 months ]
- Control of the implantable cardioverter defibrillator [ Time Frame: 12 months ]
- Analysis of major cardiovascular events [ Time Frame: 12 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient who signed the informed consent,
- Chronic stable ischemic cardiomyopathy for at least one month with a NYHA Class II-IV and/or -Angina pectoris CCS Class III or IV,
- Not a candidate for revascularization by coronary artery by-pass surgery or angioplasty,
- Left ventricular function ≤45%,
- Presence of ischemia or myocardial viability on the myocardial perfusion imaging,
- VO2 max≤ 20 ml/min/kg,
- Optimal medical therapy,
- Optimal interventional therapy (Implantable Cardiovertor Defibrillator, effort rehabilitation).
Exclusion criteria:
- Pregnancy or breastfeeding,
- Acute coronary syndrome or myocardial infarction during the last 3 months,
- Revascularization (PCI or CABG), or cardiac resynchronization during the last 3 months,
- Further revascularization planned for the next 30 days,
- LVEF >45%,
- Left intraventricular Thrombus and / or ventricular aneurysm detected by transthoracic echocardiography,
- Wall thickness in the target region <8 mm as determined by echocardiography,
- Critical Limb Ischemia stages 3 or 4,
- Inability to achieve a VO2 test,
- Not feasible peripheral arterial access for percutaneous procedure,
- Aortic stenosis (<1cm²) or aortic insufficiency (> 2 +),
- Patients with transplanted organ,
- Chronic renal failure with creatinemia ≥ 250 µmol/L,
- Severe hepatic dysfunction,
- Chronic atrial fibrillation,
- Decompensated heart failure,
- Uncontrolled Ventricular arrhythmias,
- Indication of cardiac resynchronization by multisite pacemaker or cardiac resynchronization during the last 3 months,
- Obesity preventing bone marrow aspiration or manual compression of the puncture area after bone marrow collection,
- Active uncontrolled infection
- Immuno-modulator treatment (ciclosporin, mycophenolate, mycophenolate mofetil, azathioprine, tacrolimus, anthracyclines, neupogen, hydrea, etanercept interferons, prednisolone, methylprednisolone, colchicine),
- History of cancer in the last 5 years,
- Hemopathy, hematopoietic disease,
- Haemorrhagic syndrome,
- Chronic or progressive disease that may alter the prognosis within 3 months,
- Positive serologies for Human immunodeficiency virus (HIV1-2), HTLV-1 (human T-cell lymphotrophic virus) and 2, HBV (hepatitis B virus) or HCV (hepatitis B virus).
- Allergic to xylocain.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02462330
Contacts
| Contact: Jerôme Roncalli, MD, PhD | 05 61 32 26 13 ext +33 | roncalli.j@chu-toulouse.fr | |
| Contact: Amandine Pauze | 05 61 77 84 34 | pauze.a@chu-toulouse.fr |
Locations
| France | |
| University hospital of Henri Mondor | Recruiting |
| Créteil, France, 94010 | |
| Contact: Emmanuel Teiger, MD, PhD 01 49 81 21 11 ext +33 emmanuel.teiger@hmn.aphp.fr | |
| Principal Investigator: Emmanuel Teiger, MD, PhD | |
| University hospital of Grenoble | Not yet recruiting |
| Grenoble, France, 38043 | |
| Contact: Yannick Neuder 04 76 76 84 66 ext +33 YNeuder@chu-grenoble.fr | |
| Principal Investigator: Yannick Neuder, MD, PhD | |
| University hospital of Lille | Not yet recruiting |
| Lille, France, 59037 | |
| Contact: Eric Van Belle, MD, PhD 03 20 44 59 62 ext +33 ericvanbelle@aol.com | |
| Principal Investigator: Eric Van Belle, MD, PhD | |
| University hospital of Nantes | Not yet recruiting |
| Nantes, France, 44093 | |
| Contact: Jean-Noël Trochu, MD, PhD 02 40 16 52 77 ext +33 jeannoel.trochu@chu-nantes.fr | |
| Principal Investigator: Jean-Noël Trochu, MD, PhD | |
| University hospital of Pitié-Salpêtrière | Recruiting |
| Paris, France, 75651 | |
| Contact: Richard Isnard, MD, PhD 01 42 16 30 09 ext +33 richard.isnard@psl.aphp.fr | |
| Principal Investigator: Richard Isnard, MD, PhD | |
| Cardiology Department of Rangueil Hospital - Rangueil Hospital | Recruiting |
| Toulouse, France, 31059 | |
| Contact: Jerôme Roncalli, MD, PhD 05 61 32 26 13 ext +33 roncalli.j@chu-toulouse.fr | |
| Contact: Marine Lebrin 05 61 32 37 24 ext +33 lebrin.m@chu-toulouse.fr | |
| Principal Investigator: Jerôme Roncalli, MD, PhD | |
Sponsors and Collaborators
University Hospital, Toulouse
Investigators
| Principal Investigator: | Jerôme Roncalli, MD, PhD | Toulouse University Hospital |
| Responsible Party: | University Hospital, Toulouse |
| ClinicalTrials.gov Identifier: | NCT02462330 |
| Other Study ID Numbers: |
10 142 01 |
| First Posted: | June 4, 2015 Key Record Dates |
| Last Update Posted: | July 30, 2020 |
| Last Verified: | July 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Keywords provided by University Hospital, Toulouse:
|
Mesenchymal stem cells ischemic cardiomyopathy NogaStar XP system catheter |
Additional relevant MeSH terms:
|
Cardiomyopathies Myocardial Ischemia Ischemia Pathologic Processes |
Heart Diseases Cardiovascular Diseases Vascular Diseases |